The effects of ziprasidone on regional c-Fos expression in the rat forebrain

Psychopharmacology

Volumn 184, Issue 1, 2006, Pages 13-20

  Jennings, C A ^a   Cluderay, J E ^a   Gartlon, J ^a   Cilia, J ^a   Lloyd, A ^a   Jones, D N C ^a   Southam, E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antipsychotic; c Fos immunohistochemistry; Immediate early genes; Schizophrenia; Ziprasidone

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT; PROTEIN C FOS; ZIPRASIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL DENSITY; CELL LEVEL; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FOREBRAIN; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; NEUROANATOMY; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PUTAMEN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MALE; PIPERAZINES; PROSENCEPHALON; PROTO-ONCOGENE PROTEINS C-FOS; RATS; THIAZOLES; TIME FACTORS;

EID: 29344467656     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0222-1     Document Type: Article

References (28)

1. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15(1):37-46
2. Cropley J, Gibson V, Rourke C, Hatcher P, Jones D.N.C, Reavill C (2003) Pharmacological profile of atypical antipsychotic drugs. J Psychopharmacol 17 Suppl 3
3. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6 week placebo controlled study. Neuropsychopharmacology 20:491-505
4. Daniel DG, Copeland LF (2000) Ziprasidone: a comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Invest Drugs 9(4):819-828
5. Deutch AY, Lee MC, Iadorola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332-341
6. Deutch AY (1996) Sites and mechanism of action of antipsychotic drugs as revealed by immediate early gene expression. In: Csernansky JG (ed) Antipsychotics. Springer, Berlin Heidelberg New York, pp117-161
7. 2dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37:287-294
8. Gunasekara NS, Spencer CM, Keating GM (2002) Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 62(8):1217-1251
9. 2A receptor antagonist, attenuates phencyclidine- induced Fos expression in discrete regions of rat brain. Eur J Pharmacol 417(3):189-194
10. 1A receptor agonist, blocks haloperidol induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27(5):515-518
11. 1Areceptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain. Eur J Pharmacol 455(2-3):109-115
12. 2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 13(6):831-835
13. 3 receptor selective RGH-1756. Neuropharmacology 40(3):383-393
14. Mansbach RS, Carver J, Zorn SH (2001) Blockade of drug induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 69:535-542
15. 2 pKi values. J Pharmacol Exp Ther 251:238-246
16. Merchant KM, Figur LM, Evans DL (1996) Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Cereb Cortex 6(4):561-570
17. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. Academic, San Diego, California, USA
18. 2C receptor antagonist. J Psychopharmacol 126:572-574
19. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328
20. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
21. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197-201
22. 3 receptor in schizophrenia and in antipsychotic drug actions. Brains Res Rev 31:277-287
23. 2A/2Creceptors in the clozapine-induced Fos-protein expression in rat forebrain regions. Eur J Pharmacol 408(1):11-17
24. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, Mclean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
25. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004) Testing the validity of c-Fos expression profiling to aid the classification of psychoactive drugs. Psychopharmacology 171(3):306-321
26. Tremblay P-O, Gervais J, Rouillard C (1998) Modification of haloperidol-induced pattern of c-Fos expression by serotonin agonists. Eur J Neurosci 10:3546-3555
27. Wadenberg ML (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH23390 in the rat. J Neural Transm 89:4-9
28. Wan W, Ennulat DJ, Cohen BM (1995) Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 688(1-2):95-104